Market Place
Sourcing Support
MHRA Class 2 Medicines Recall: Irbesartan & Losartan containing products : PSNC
18 Jun 2021 //
FIRSTWORDPHARMA
As companies dump money into manufacturing, where they find trained workers
03 Jun 2021 //
ENDPTS
#ASCO21: Bristol Myers` solo, dual I/O regimens best chemo alone
03 Jun 2021 //
ENDPTS
J&J elbows into crowded MS market with FDA nod for Ponvory
19 Mar 2021 //
FIERCEPHARMA
Another Keytruda combo tops standard of care in advanced kidney cancer
16 Feb 2021 //
ENDPTS
BMS, Exelixis` Opdivo-Cabometyx continues kidney cancer streak
11 Feb 2021 //
FIERCE PHARMA
FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment
10 Feb 2021 //
PHARMTECH
Bristol Myers Squibb can grow through Revlimid generics, execs insist
06 Feb 2021 //
FIERCE PHARMA
Hematology chief Ahmed leaves BMS—Chutes & Ladders
15 Jan 2021 //
FIERCE BIOTECH
Foreign I-O drugs strike out on Chinese coverage
30 Dec 2020 //
FIERCE PHARMA
European Medicines Agency Validates Bristol Myers Application for Zeposia
28 Dec 2020 //
BUSINESSWIRE
European Medicines Agency Validates Bristol Myers Application for Zeposia
28 Dec 2020 //
BUSINESSWIRE
FDA dings Bristol Myers` CAR-T plant ahead of key decision
08 Dec 2020 //
FIERCE PHARMA
FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs
16 Nov 2020 //
REUTERS
Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes
09 Nov 2020 //
BUSINESSWIRE
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
04 Nov 2020 //
BIOSPACE
Bristol Myers Squibb Announces Positive Topline Result from Pivotal Ph3 Zeposia
02 Jun 2020 //
BUSINESSWIRE
Versant-backed, Bristol Myers-stamped Repare Therapeutics guns for $100M IPO
01 Jun 2020 //
ENDPTS
BMS jumps into synthetic lethality with $65M Repare deal
28 May 2020 //
FIERCE BIOTECH
Repare Therapeutics Announces Multi-Target Discovery Collaboration with BMY`S
26 May 2020 //
BUSINESSWIRE
BMS, Exelixis score a kidney cancer win. But can they nab share?
21 Apr 2020 //
FIERCE PHARMA
BMS` Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
08 Apr 2020 //
BUSINESSWIRE
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb
31 Mar 2020 //
ENDPTS
For CAR-T, coronavirus brings uneven impact to studies, treatment
28 Mar 2020 //
BIOSPECTRUMASIA
BMS Investor Fact Sheet related to COVID-19
26 Mar 2020 //
SEC
Charles Bancroft makes quick leap from Bristol Myers exec team to GSK
20 Mar 2020 //
ENDPTS
BMS reaches tentative deal to end Medicaid rebate lawsuit
29 Feb 2020 //
FIERCE PHARMA
Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes
03 Dec 2019 //
FIERCE PHARMA
MHRA gives Bristol Labs the all-clear
11 Jun 2019 //
FIERCE PHARMA
Merck`s Keytruda stumbles again in stomach cancer
26 Apr 2019 //
FIERCE PHARMA
Bristol Laboratories Ltd. Fails EDQM Inspection
09 Jan 2019 //
EDQM
Goldfinch poaches AstraZeneca research executive Tony Johnson for CEO
05 Dec 2017 //
FIERCE BIOTECH
Bristol Laboratories (Berkhamsted) Fails EDQM Inspection
03 Oct 2017 //
EDQM
Bristol Laboratories (Luton) Fails EDQM Inspection
25 Aug 2017 //
EMA
Bristol Laboratories Limited (Peterlee) Fails EDQM Inspection
24 Aug 2017 //
EDQM
BMS and Clovis join forces in PARP combo race
01 Aug 2017 //
PMLIVE
Bristol`s Nivolumab Approved in EU For lung cancer (NSCLC)
28 Jul 2015 //
FLICKER
